Sanofi (ENXTPA:SAN) Stock May Be Undervalued On Upgraded 2026 Guidance

Sanofi stock is down 9.5% year to date, yet the broader valuation checks still point to shares that screen on the cheap side rather than expensive. Recent headlines around strong product momentum on one side and pipeline setbacks on the other add extra focus to whether the current price fairly reflects the risk and reward mix.

• Sanofi has declined 9.5% year to date, which means investors are looking at a stock that has lagged while the underlying valuation signals suggest potential mispricing.
• Stronger sales growth from key Pharma launches can support confidence in future earnings, while the decision to discontinue the eczema drug amlitelimab after a Phase III setback underlines ongoing pipeline risk that can cap how much investors are willing to pay.
• On Simply Wall St's checks, Sanofi looks undervalued in 6 of 6 areas. This means the broader valuation framework leans toward the stock being priced cautiously rather than generously. See the 6/6 valuation checks for detail.

The issue now is whether Sanofi's current share price already reflects these mixed signals on growth and risk or if the stock still offers a margin of safety.

Find out why Sanofi's -2.1% return over the last year is lagging behind its peers.

Does Sanofi Look Undervalued on Earnings?

The P/E ratio is a useful yardstick for Sanofi because earnings are a core focus for investors in large, established Pharma companies. Right now, Sanofi trades at about 18.5x earnings, which sits slightly below both the Pharmaceuticals industry average of around 20.9x and the peer group average of about 18.7x. On simple comparisons, the stock is not priced at a premium to its sector even though it competes with other large global drug makers.

On Simply Wall St's more tailored fair multiple, which factors in Sanofi's growth profile, margins, size and risks, the stock screens on an implied P/E of 37.1x. That is significantly higher than the current 18.5x, so the market is assigning a sizeable discount to what this framework suggests. Despite the recent guidance upgrade on sales and earnings for 2026, the P/E multiple still sits well below this fair value marker.

On the P/E measure, Sanofi stock currently looks undervalued relative to both its industry and its modelled fair multiple.

See what the numbers say about this price — find out in our valuation breakdown.

The Sanofi Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Sanofi pick up where the valuation puzzle leaves off by spelling out the future paths for growth, margins and earnings that would need to play out for the stock to be worth materially more or materially less than today’s price, based on scenarios shared on the Community page. Where a single ratio or valuation model offers one number, these narratives lay out the underlying future it assumes so you can track whether that story still holds over time.

One of the top community narratives on Sanofi: 23% undervalued

"Continued investment in products, acquisitions, and portfolio streamlining is positioning Sanofi for long-term growth in high-value therapeutic areas..."

Read one of the top narratives on Sanofi

Do you think there's more to the story for Sanofi? Head over to our Community to see what others are saying!

The Bottom Line

Sanofi still screens as undervalued on market multiples, even after factoring in the recent product wins and the setback in the eczema program. The key question is whether that discount is compensation for real execution and pipeline risk or whether it reflects overly cautious sentiment toward large Pharma stocks today. What matters from here is whether Sanofi can keep delivering on earnings and product momentum strongly enough for investors to reconsider the current P/E gap. The crux of the debate is whether that gap closes through a higher valuation multiple or whether the concerns behind the discount prove justified.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com